{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:24:51Z","timestamp":1769232291274,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,4,19]],"date-time":"2015-04-19T00:00:00Z","timestamp":1429401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00277-015-2367-2","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T05:46:27Z","timestamp":1429335987000},"page":"1363-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?"],"prefix":"10.1007","volume":"94","author":[{"given":"David","family":"Gurrea Salas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine T.","family":"Tauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meinolf","family":"Suttorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,19]]},"reference":[{"key":"2367_CR1","unstructured":"Altman AJ (2000) Chronic leukemias of childhood. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincot Williams & Wilkins (LWW) pp 591-614"},{"issue":"8","key":"2367_CR2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","volume":"119","author":"JR Andolina","year":"2012","unstructured":"Andolina JR, Neudorf SM, Corey SJ (2012) How I treat childhood CML. Blood 119(8):1821\u20131830","journal-title":"Blood"},{"key":"2367_CR3","unstructured":"Baccarani M (2010) Calculation of relative risk of CML patients http:\/\/www.leukemia-net.org\/content\/leukemias\/cml\/cml_score\/index_eng.html"},{"issue":"S7","key":"2367_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann JL et al (2012) Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(S7):72\u201377","journal-title":"Ann Oncol"},{"issue":"9","key":"2367_CR5","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.leukres.2012.05.011","volume":"36","author":"M Breccia","year":"2012","unstructured":"Breccia M, Finsinger P, Loglisci G et al (2012) The EUTOS score identifies chronic myeloid leukemia patients treated with imatinib first or second line. Leuk Res 36(9):e209\u2013e210","journal-title":"Leuk Res"},{"key":"2367_CR6","unstructured":"Castagneti F, Gugliotta G, Palandri F et al (2012) EUTOS score is predictive for survival and outcome of patients with early chronic phase chronic myeloid leukemia treated with nilotinib-base regimens. Haematologica 97(Suppl. 1, abstract #193):76"},{"issue":"4","key":"2367_CR7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/1097-0142(19830815)52:4<721::AID-CNCR2820520426>3.0.CO;2-X","volume":"52","author":"H Castro-Malaspina","year":"1983","unstructured":"Castro-Malaspina H, Schaison G, Breire J et al (1983) Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors. Cancer 52(4):721\u2013727","journal-title":"Cancer"},{"issue":"10","key":"2367_CR8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ajh.23501","volume":"88","author":"M Cerrano","year":"2013","unstructured":"Cerrano M, Cris\u00e0 E, Pregno P et al (2013) Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients. Am J Hematol 88(10):838\u2013842","journal-title":"Am J Hematol"},{"issue":"1","key":"2367_CR9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0037-1963(03)70045-6","volume":"40","author":"J Cortes","year":"2003","unstructured":"Cortes J, Kantarjian H (2003) Advanced-phase chronic myeloid leukemia. Semin Hematol 40(1):79\u201386","journal-title":"Semin Hematol"},{"issue":"4","key":"2367_CR10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","volume":"102","author":"K Cwynarski","year":"2003","unstructured":"Cwynarski K, Roberts IA, Iacobelli S et al (2003) Stem cell transplantation for chronic myeloid leukemia in children. Blood 102(4):1224\u20131231","journal-title":"Blood"},{"issue":"1","key":"2367_CR11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.12977","volume":"167","author":"J Fuente De la","year":"2014","unstructured":"De la Fuente J, Baruchel A, Biondi A, on behalf of the International BFM Group Study Group Chronic Myeloid Leukaemia Committee et al (2014) How I manage CML in children. Guidelines for the management of chronic myeloid leukaemia in children and young people up to the age of 18\u00a0years. Br J Haematol 167(1):33\u201347","journal-title":"Br J Haematol"},{"issue":"23","key":"2367_CR12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"issue":"3","key":"2367_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z et al (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164\u2013172","journal-title":"N Engl J Med"},{"issue":"1","key":"2367_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow, results of a phase II study. Leukemia 27(1):107\u2013112","journal-title":"Leukemia"},{"issue":"8","key":"2367_CR15","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","volume":"110","author":"JM Goldman","year":"2007","unstructured":"Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110(8):2828\u20132837","journal-title":"Blood"},{"issue":"11","key":"2367_CR16","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","volume":"28","author":"JM Goldman","year":"2010","unstructured":"Goldman JM, Majhail NS, Klein JP et al (2010) Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 28(11):1888\u20131895","journal-title":"J Clin Oncol"},{"issue":"4","key":"2367_CR17","first-page":"513","volume":"91","author":"A Gratwohl","year":"2006","unstructured":"Gratwohl A, Brand R, Apperley J et al (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EMBT). Haematologica 91(4):513\u2013521","journal-title":"Haematologica"},{"issue":"21","key":"2367_CR18","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591\u20135599","journal-title":"Blood"},{"issue":"9","key":"2367_CR19","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26(9):2096\u20132102","journal-title":"Leukemia"},{"issue":"11","key":"2367_CR20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirmann M, Hehlman R et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing Committee for the collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850\u2013858","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2367_CR21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffman V et al (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692","journal-title":"Blood"},{"key":"2367_CR22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","volume":"62","author":"N Hijiya","year":"2015","unstructured":"Hijiya N, Millot F, Suttorp M (2015) Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin N Am 62:107\u2013119","journal-title":"Pediatr Clin N Am"},{"issue":"11","key":"2367_CR23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000163070","volume":"31","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A (2008) Prognostic factors in chronic myeloid leukemia (CML). Onkologie 31(11):576\u2013578","journal-title":"Onkologie"},{"key":"2367_CR24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","volume":"2011","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A (2011) Educational session: managing chronic myeloid leukemia as a chronic disease. Hematol Am Soc Hematol Educ Program 2011:128\u2013135","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"2367_CR25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054\u20131061","journal-title":"Leukemia"},{"issue":"10","key":"2367_CR26","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffman","year":"2013","unstructured":"Hoffman VS, Baccarani M, Lindoerfer D et al (2013) The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 27(10):2016\u20132022","journal-title":"Leukemia"},{"issue":"19","key":"2367_CR27","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"T Hughes","year":"2010","unstructured":"Hughes T, Hochhaus A, Brandford S et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758\u20133765","journal-title":"Blood"},{"issue":"4","key":"2367_CR28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","volume":"108","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Cortes J, Kantarjian MH et al (2006) Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108(4):1421\u20131423","journal-title":"Blood"},{"issue":"19","key":"2367_CR29","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","volume":"119","author":"E Jabbour","year":"2012","unstructured":"Jabbour E, Cortes J, Nazha A et al (2012) EUTOS score is not predictive for survival and outcome in patients with early chronic phase of chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 119(19):4524\u20134526","journal-title":"Blood"},{"issue":"1","key":"2367_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M et al (2014) Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML-study IV. Ann Hematol 93(1):71\u201380","journal-title":"Ann Hematol"},{"issue":"12","key":"2367_CR31","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","volume":"53","author":"KC Lakshmaiah","year":"2012","unstructured":"Lakshmaiah KC, Bhise R, Purohit S et al (2012) Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 53(12):2430\u20132433","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2367_CR32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000343384","volume":"129","author":"R Latagliata","year":"2013","unstructured":"Latagliata R, Isidori A, Breccia M et al (2013) Complete clearance of Ph\u2009+\u2009metaphases after 3\u00a0months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Acta Haematol 129(2):126\u2013134","journal-title":"Acta Haematol"},{"issue":"29","key":"2367_CR33","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","volume":"29","author":"D Marin","year":"2011","unstructured":"Marin D, Ibrahim AR, Goldman JM (2011) European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 29(29):3944\u20133945","journal-title":"J Clin Oncol"},{"issue":"3","key":"2367_CR34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C et al (2012) Assessment of BRC-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30(3):232\u2013238","journal-title":"J Clin Oncol"},{"issue":"140","key":"2367_CR35","first-page":"2004","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J et al (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116(140):2004\u20132473","journal-title":"Pediatrics"},{"issue":"20","key":"2367_CR36","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","volume":"29","author":"F Millot","year":"2011","unstructured":"Millot F, Baruchel A, Guilhot J et al (2011) Imatinib is effective in children with previously treated chronic myeloid leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 29(20):2827\u20132832","journal-title":"J Clin Oncol"},{"key":"2367_CR37","doi-asserted-by":"crossref","unstructured":"Millot F, Guilhot J, Suttorp M et al (2014) The experience of the international registry for chronic myeloid leukemia (CML) in children and adolescents (I-CML-Ped Study): prognostic consideration. Blood 124 (21), ASH annual meeting abstract #521","DOI":"10.1182\/blood.V124.21.521.521"},{"issue":"2","key":"2367_CR38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2009.09.022","volume":"16","author":"H Muramatsu","year":"2010","unstructured":"Muramatsu H, Kojima S, Yoshimi A et al (2010) Outcome of 125 children with chronic myelogeneous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant 16(2):231\u2013238","journal-title":"Biol Blood Marrow Transplant"},{"key":"2367_CR39","unstructured":"National Comprehensive Cancer Network (NCCN) (2013) http:\/\/www.nccn.org\/patients\/guidelines\/cml\/index.html NCCN practical guidelines in oncology (NCCN Guidelines) (2013). Accessed 13 Sep 2013"},{"issue":"14","key":"2367_CR40","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C et al (2013) Combining BCR-ABL1 transcript levels at 3 and 6\u00a0months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739\u20132742","journal-title":"Blood"},{"issue":"2","key":"2367_CR41","first-page":"78","volume":"169","author":"RA O\u2019Reilly","year":"1998","unstructured":"O\u2019Reilly RA (1998) Splenomegaly in 2505 patients in a large university medical center from 1913 to 1995. 1913 to 1962: 2056 patients. West J Med 169(2):78\u201387","journal-title":"West J Med"},{"issue":"8","key":"2367_CR42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.23238","volume":"87","author":"L Ohm","year":"2012","unstructured":"Ohm L, Arvidsson I, Barbany G et al (2012) Early landmark analysis of imatinib treatment in CML chronic phase: less than 10\u00a0% BCR-ABL by FISH at 3\u00a0months associated with improved long-term clinical outcome. Am J Hematol 87(8):760\u2013765","journal-title":"Am J Hematol"},{"issue":"2","key":"2367_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5430\/jhm.v2n2p25","volume":"2","author":"AA Oyekunle","year":"2012","unstructured":"Oyekunle AA, Osho PO, Aneke JC et al (2012) The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukemia in the imatinib era. J Hematol Malign 2(2):25\u201332","journal-title":"J Hematol Malign"},{"issue":"7","key":"2367_CR44","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju N, Kantarjian H, Shan J et al (2012) Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029\u20131035","journal-title":"Haematologica"},{"key":"2367_CR45","doi-asserted-by":"crossref","unstructured":"Raman GR, Nasaka S, Gundeti S et al (2014) Effectiveness in predicting response and outcome with three prognostic scoring systems in pediatric CML on upfront imatinib. Blood 124 (21), ASH annual meeting abstract #4549","DOI":"10.1182\/blood.V124.21.4549.4549"},{"issue":"1","key":"2367_CR46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.6004\/jnccn.2012.0011","volume":"10","author":"G Saglio","year":"2012","unstructured":"Saglio G, Fava C (2012) Practical monitoring of chronic myelogenous leukemia: when to change treatment. J Natl Compr Cancer Netw 10(1):121\u2013129","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"2367_CR47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"6","key":"2367_CR48","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V66.6.1352.1352","volume":"66","author":"JE Sokal","year":"1985","unstructured":"Sokal JE, Baccarani M, Tura S et al (1985) Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood 66(6):1352\u20131357","journal-title":"Blood"},{"issue":"1","key":"2367_CR49","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D et al (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25(1):49\u201361","journal-title":"Semin Hematol"},{"key":"2367_CR50","unstructured":"Steegmann JL, Casado LF (2012) The new EUTOS score has prognostic value in the treatment of chronic myeloid leukemia (CML) outside clinical trials. Blood E-Letter published online January 27, 2012"},{"key":"2367_CR51","unstructured":"Suttorp M (2006) Protocol for standardized diagnostic procedures, registration and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). CML-paed-II Study. http:\/\/www.kinderkrebsinfo.de\/sites\/kinderkrebsinfo\/content\/e1676\/e9032\/e1758\/e5368\/download38391\/ClinicalTrialProtocolCML-paed-IIStudyDocumentation,ECVger.pdf (2006). Accessed 13 Sep 2013"},{"key":"2367_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/asheducation-2010.1.368","volume":"2010","author":"M Suttorp","year":"2010","unstructured":"Suttorp M, Millot F (2010) Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation. Hematol Am Soc Hematol Edu Program 2010:368\u2013376","journal-title":"Hematol Am Soc Hematol Edu Program"},{"issue":"6","key":"2367_CR53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1239529","volume":"221","author":"M Suttorp","year":"2009","unstructured":"Suttorp M, Claviez A, Bader P et al (2009) Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed-I. Klin Padiatr 221(6):351\u2013357","journal-title":"Klin Padiatr"},{"issue":"Suppl 1","key":"2367_CR54","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.bbmt.2010.09.003","volume":"17","author":"M Suttorp","year":"2011","unstructured":"Suttorp M, Yaniv I, Schultz KR (2011) Controversies in the treatment of CML in children and adolescents. TKIs versus BMT. Biol Blood Marrow Transplant 17(Suppl 1):S115\u2013S122","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2367_CR55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11899-012-0113-6","volume":"7","author":"M Suttorp","year":"2012","unstructured":"Suttorp M, Eckardt T, Tauer JT et al (2012) Management of chronic myeloid leukemia in childhood. Curr Hematol Malig Rep 7(2):116\u2013124","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"2367_CR56","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood.V122.21.2725.2725","volume":"122","author":"M Suttorp","year":"2013","unstructured":"Suttorp M, Glauche I, Gurrea Salas D et al (2013) Scoring systems for predicting outcome of chronic myeloid leukemia in adults are poorly informative in pediatric patients treated with imatinib (abstract). Blood 122(21):2725","journal-title":"Blood"},{"issue":"6","key":"2367_CR57","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/14656566.2012.671296","volume":"13","author":"MF Tanaka","year":"2012","unstructured":"Tanaka MF, Kantarjian H, Cortes J et al (2012) Treatment options for chronic myeloid leukemia. Expert Opin Pharmacother 13(6):815\u2013828","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2367_CR58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-012-1043-8","volume":"95","author":"PC Trask","year":"2012","unstructured":"Trask PC, Mitra D, Iyer S et al (2012) Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol 95(5):535\u2013544","journal-title":"Int J Hematol"},{"issue":"1-2","key":"2367_CR59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000089476","volume":"115","author":"W Verbeek","year":"2006","unstructured":"Verbeek W, K\u00f6nig H, Boehm J et al (2006) Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9\u00a0years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukemia. Acta Haematol 115(1-2):109\u2013112","journal-title":"Acta Haematol"},{"issue":"Suppl 3","key":"2367_CR60","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","volume":"129","author":"K Williams","year":"2012","unstructured":"Williams K, Thomson D, Seto I et al (2012) Standard 6: age groups for pediatric trials. Pediatrics 129(Suppl 3):S153\u2013S160","journal-title":"Pediatrics"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2367-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2367-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2367-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T02:00:55Z","timestamp":1598925655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2367-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,19]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2367-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,19]]}}}